16001166

Source:http://linkedlifedata.com/resource/pubmed/id/16001166

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0026336, umls-concept:C0026339, umls-concept:C0031740, umls-concept:C0302350, umls-concept:C0591833, umls-concept:C0596087, umls-concept:C0762592, umls-concept:C0970963, umls-concept:C1999177, umls-concept:C2931822
pubmed:issue	6
pubmed:dateCreated	2005-10-5
pubmed:abstractText	Photodynamic therapy (PDT) is a promising therapeutic modality using a tumor localizing photosensitizer and light to destroy tumor cells. A major limitation of PDT is tumor recurrence, which is partly due to neovascularization.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Perylene, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/SU 5416, http://linkedlifedata.com/resource/pubmed/chemical/SU 6668, http://linkedlifedata.com/resource/pubmed/chemical/hypericin
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0344-5704
pubmed:author	pubmed-author:BalramChowbayC, pubmed-author:LyeKaren Yee KarKY, pubmed-author:MooreShirleyS, pubmed-author:OlivoMaliniM, pubmed-author:SharmaAmarnathA, pubmed-author:ZhouQingyuQ
pubmed:issnType	Print
pubmed:volume	56
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	569-77
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:16001166-Adenocarcinoma, pubmed-meshheading:16001166-Angiogenesis Inhibitors, pubmed-meshheading:16001166-Animals, pubmed-meshheading:16001166-Antineoplastic Agents, pubmed-meshheading:16001166-Chemotherapy, Adjuvant, pubmed-meshheading:16001166-Drug Screening Assays, Antitumor, pubmed-meshheading:16001166-Gene Expression, pubmed-meshheading:16001166-Indoles, pubmed-meshheading:16001166-Male, pubmed-meshheading:16001166-Mice, pubmed-meshheading:16001166-Mice, Inbred BALB C, pubmed-meshheading:16001166-Mice, Nude, pubmed-meshheading:16001166-Nasopharyngeal Neoplasms, pubmed-meshheading:16001166-Neoplasm Transplantation, pubmed-meshheading:16001166-Neoplasms, Experimental, pubmed-meshheading:16001166-Perylene, pubmed-meshheading:16001166-Photochemotherapy, pubmed-meshheading:16001166-Protein-Tyrosine Kinases, pubmed-meshheading:16001166-Proteins, pubmed-meshheading:16001166-Pyrroles, pubmed-meshheading:16001166-Survival Rate
pubmed:year	2005
pubmed:articleTitle	Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
pubmed:affiliation	Laboratory of Clinical Pharmacology Division of Clinical Trials & Epidemiological Sciences, National Cancer Centre, 11, Hospital Drive, 169610, Singapore.
pubmed:publicationType	Journal Article, Clinical Trial, Phase I